Recently, transcriptional silencing by aberrant methylation of promoter region of the CCND2 gene has been found in gastric cancer [20], breast cancer [38, 40], prostate cancer [39, 41], lung cancer [18], and Epstein–Barr virus-positive Burkitt's lymphoma [42]. This evidence concerns the gene CCND2 and Burkitt lymphoma.